ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) announces a conference call on November 12, 2020, at 8:30 AM ET to discuss its financial results for Q3 2020 and provide business updates. The call can be accessed via phone or live webcast. The company focuses on developing targeted antibody drug conjugates (ADCs) for treating hematological malignancies and solid tumors. Key product candidates include Loncastuximab tesirine, which demonstrated a 48.3% overall response rate in a pivotal clinical trial, and Camidanlumab tesirine, with an 86.5% response rate in Hodgkin lymphoma patients.

Positive

• Loncastuximab tesirine showed a 48.3% overall response rate in a pivotal Phase 2 trial.
• Camidanlumab tesirine demonstrated an 86.5% overall response rate in a Phase 1 trial for Hodgkin lymphoma.
• Multiple PBD-based ADCs are in ongoing clinical trials across various stages.

Negative

• None.

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, November 12, 2020 at 8:30 am ET to report financial results for the third quarter ended September 30, 2020 and provide business updates.

To access the live call, please dial 833-249-8403 (domestic) or + 41 225675632 (international). A live webcast of the presentation will be available under “Events and Presentations” on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available after the completion of the event and for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.

Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company’s lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR), which exceeded the target primary endpoint. In September 2020, ADC Therapeutics submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval for Lonca for the treatment of patients with relapsed or refractory DLBCL. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company’s second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) after having shown in a Phase 1 clinical trial an 86.5% ORR in HL patients at the dose selected for Phase 2. The Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.